Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07215273 · ClinicalTrials.gov registry record · Phase 2
Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections
A Phase 2 study of Suspected Invasive Mould Infection, sponsored by Elion Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 2
- Study locations
NCT07215273: Recruiting Phase 2 study of Suspected Invasive Mould Infection, sponsored by Elion Therapeutics.
NCT07215273 is a Phase 2 study of Suspected Invasive Mould Infection that is actively recruiting participants, run by Elion Therapeutics. The registered enrollment target is 80 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07215273, a Phase 2 study of Suspected Invasive Mould Infection, is actively recruiting participants, sponsored by Elion Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine if EL219 is safe and effective compared to the standard of care for early treatment of suspected invasive mould infection.
Primary Outcome
All-cause mortality at Day 21 (plus or minus 3 days) in the Intent-to-Treat (ITT) analysis set.
Conditions Studied
Interventions
- DRUG EL219
- DRUG Antifungal Comparator
Study Locations (2)
Missouri
- Washington U. - St Louis
Texas
- U. of Texas, MD Anderson - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-02 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
What NCT07215273 shows while recruiting
NCT07215273 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower).
The record links to 1 condition, with Suspected Invasive Mould Infection appearing as the primary indexed condition, and to 2 interventions - of which EL219 is the first listed.
NCT07215273 reports a single indexed study location in Missouri, Texas.
Frequently Asked Questions
What is clinical trial NCT07215273 about?
NCT07215273 is a clinical study titled "Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections". The purpose of this study is to determine if EL219 is safe and effective compared to the standard of care for early treatment of suspected invasive mould infection.
What is the current status of trial NCT07215273?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2026-02. Estimated completion is 2026-11.
What conditions does trial NCT07215273 study?
This clinical trial studies the following conditions: Suspected Invasive Mould Infection.
What interventions are being tested in trial NCT07215273?
The interventions under investigation include: EL219 (DRUG), Antifungal Comparator (DRUG).
Who is sponsoring clinical trial NCT07215273?
This trial is sponsored by Elion Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07215273 being conducted?
This trial has 2 study locations across Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07215273's enrollment target sits among peer trials
80 842nd of 2000 higher than 1,117 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia